Today, AstraZeneca announced that the acquisition of Icosavax is complete. This is an exciting opportunity to combine our expertise and capabilities and bring next-generation vaccines to people around the word.

Icosavax reports 3Q23 financial results and provides corporate update, including candidate selection for SARS-CoV-2 and influenza programs, highlighting company’s antigen design capabilities.

ir.icosavax.com/news-releases/…

$ICVX #vaccines #VLPvaccines

Icosavax to Participate in the Guggenheim Healthcare Talks 5th Annual Inflammation, Neurology & Immunology (INI) Conference

ir.icosavax.com/news-releases/…

$ICVX #vaccines #VLPvaccines #RSVhMPV

Today we reported 2Q2023 financial results and provided a corporate update. In addition to the clinical progress we have made with our #VLPvaccine candidates for #RSV and #RSV hMPV, we also appointed Dr. M. Amin Khan as EVP, Head of R&D.

ir.icosavax.com/news-releases/…

$ICVX

Today we shared new data from our Phase 1b extension trial of IVX-121 against #RSV in older adults. Data support potential differentiation on durability with our VLP platform and lead candidate IVX-A12 for #RSV hMPV.

ir.icosavax.com/news-releases/…

$ICVX #VLPvaccines

Icosavax Announces Positive Topline Interim Phase 1/1b Results for VLP Vaccine Candidate IVX-121 Against RSV

investors.icosavax.com/news-releases/…

$ICVX #vaccines #respiratory #RSV

New Type of Vaccines Could Help Against More Respiratory Illnesses

news.utexas.edu/2022/03/14/new…

Icosavax Provides Corporate Update and Anticipated Milestones for 2022

investors.icosavax.com/news-releases/…

$ICVX #vaccines #respiratory #SARSCoV2 #biotech #Seattle

Preparing for the next plague. Whether pan-vaccines or antibodies, SARS-CoV-2 is adding impetus to the race for broad-spectrum countermeasures against the world’s next infectious scourges go.nature.com/32dAJMv

Today we welcome John Shiver, Ph.D. to our Board of Directors. Dr. Shiver has more than 30 years of experience in #vaccine and pharmaceutical R&D and joins as we advance our #RSV and #COVID19 vaccine candidates in #clinicaltrials .

investors.icosavax.com/news-releases/…

#biotech #Seattle $ICVX

Vaccines and the inverted capital dilemma

rapport.bio/all-stories/va…

Icosavax Appoints Elizabeth Bekiroğlu to General Counsel investors.icosavax.com/news-releases/…

Icosavax Initiates Phase 1/1b Trial of VLP Vaccine Candidate Against Respiratory Syncytial Virus investors.icosavax.com/news-releases/…

Icosavax Executive Management at the Nasdaq closing bell ringing ceremony on August 11, 2021.

#nasdaq #closingbell #icosavax #biotech #vaccine

Come grow with us! If you are interested in #globalhealth and want to help protect the world from life-threatening respiratory viruses, check out our open positions.

icosavax.com/careers/

#Seattle #COVID19 #RSV #vaccine #biotech #hiring #recruitment #jobopenings #careers

July 29, 2021. Times Square, New York, NY.

Icosavax Announces Pricing of Upsized Initial Public Offering businesswire.com/news/home/2021…

Icosavax Appoints Thomas J. Russo Chief Financial Officer

icosavax.com/news/icosavax-…

#biotech #lifesciences #vaccine s #innovation #vaccine #seattle #biotech

Icosavax Initiates Phase 1/2 Trial of COVID-19 VLP Vaccine Candidate

icosavax.com/news/icosavax-…

#vaccines #respiratory #COVID19 #SARSCoV2 #clinicaltrials #biotech #Seattle

We just posted two new #job openings! If you are passionate about #globalhealth and experienced in #vaccine development, check out our #career s page: icosavax.com/careers/

#Seattle #COVID19 #RSV #respiratory #biotech #job s #hiring #career #nowhiring #recruitment #recruiting